Carbonic Anhydrase IX is generally overexpressed in such tumours and CAIX has been proven to be a good selection criteria for response to interleukin-2-based immunotherapy (Atkins et al, 2005; Patard et al, 2008b). This evidence concerns the gene CA9 and neoplasm.